Editorial

High bleeding risk – the clinical context matters

EuroIntervention 2021;17:e867-e868. DOI: 10.4244/EIJV17I11A145

Mamas  A. Mamas
Mamas A. Mamas1, FRCP, DPhil; Sonya N. Burgess2, MBChB, PhD
1. Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Stoke-on-Trent, United Kingdom; 2. Department of Cardiology, Nepean Hospital and University of Sydney, Sydney, NSW, Australia
The selection of optimal antiplatelet therapy following percutaneous coronary intervention (PCI) requires careful consideration, balancing the future risks of ischaemic and major bleeding events. This balance does not remain constant but varies over time depending on the clinical characteristics of the patient, the indication for PCI, lesion and procedural complexity and antithrombotic regimes prescribed1.

Major bleeding represents one of the most common complications observed following PCI and is associated with a threefold increase in the risk of mortality and major adverse cardiovascular events (MACE)2, contributing to more than one in ten of all in-hospital PCI deaths3. Therefore, avoidance of ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Post-stenting optimisation techniques in bifurcation percutaneous coronary interventions: much remains to be explored

Latest news